Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case

Summary We evaluated the cost‐effectiveness and the budget impact of new DAA‐based regimen use in France. A Markov model simulated chronic hepatitis C (CHC) treatment interventions with IFN‐based and IFN‐free regimens at stage of fibrosis ≥F3, ≥F2 or regardless of fibrosis stage, and treatment eithe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of viral hepatitis 2016-10, Vol.23 (10), p.767-779
Hauptverfasser:	Deuffic-Burban, S., Obach, D., Canva, V., Pol, S., Roudot-Thoraval, F., Dhumeaux, D., Mathurin, P., Yazdanpanah, Y.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antiviral Agents - economics Antiviral Agents - therapeutic use budget impact analysis Budgets chronic hepatitis C cohort Markov model Cost analysis Cost-Benefit Analysis cost-effectiveness analysis Cross-Sectional Studies Female France Genotype Hepacivirus - classification Hepacivirus - genetics Hepatitis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon interferon-free direct-acting antiviral agents Male Middle Aged Protease Inhibitors - economics Protease Inhibitors - therapeutic use Quality-Adjusted Life Years Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!